Cellbxhealth PLC Announces Holding(s) in Company 
Bitech Technologies Signs Letter of Intent with Value Added Reseller Paladin Power
Costa Mesa, CA, June 22, 2022 (GLOBE NEWSWIRE) -- Bitech Technologies Corporation (formerly, Spine Injury Solutions, Inc) (the “Company”), a...
Nanomix Initiates New Clinical Study for the eLab S1 Panel
Study incorporates the use of the Nanomix eLab® S1 Panel within the Emergency Department of Hospital Clinico San Carlos in...
ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products
The Company’s improved, new Vitastem products have recently begun large scale productionLOS ANGELES, June 22, 2022 (GLOBE NEWSWIRE) -- ViaDerma,...
Biora Therapeutics Announces Presentation at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
SAN DIEGO, June 22, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,...
Berkeley Lights to Participate at the 27th European Society for Animal Cell Technology Meeting
Lonza and Edinburgh Genome Foundry to present their high-throughput single-cell screening workflow use cases using the Beacon® PlatformEMERYVILLE, Calif., June...
Healthy Extracts’ WHITNEY JOHNS ACTIVE™ Clinically Proven to Enhance Physical Performance by Increasing Nitric Oxide by 73% and Oxygen Consumption by 24%
Image 1 Whitney Johns ACTIVELAS VEGAS, June 22, 2022 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator...
CytoDyn to Hold Webcast to Provide a Quarterly Company Update
VANCOUVER, Washington, June 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company...
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation
Company to discuss positive topline and additional clinical data for CY6463 in MELAS patients Mitochondrial disease clinician-researcher, Amel Karaa, M.D.,...
Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial
BMF-219, a covalent menin inhibitor, is the first menin inhibitor administered to patients with relapsed/refractory (R/R) multiple myeloma (MM)Patients with...
Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) to Sagard Healthcare Partners and Oaktree
Company executes on strategy to extend cash runway by monetizing non-core assetsTotal transaction value of $85 million; at least $80...
Simply Better Brands Corp. Expands its Strategic Partnership With New Frontier Presents to Include Metaverse Shopping
PureKana Wellness, a Simply Better Brands asset, has expanded its current metaverse footprint by launching its Metaverse Shop Image 1...
Rhythm Pharmaceuticals Launches IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger Associated with POMC or LEPR Deficiency
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the...
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative,...
In Honor of PTSD Awareness Month Recovery First Wants Veterans and First Responders to Know They are Not Alone
HOLLYWOOD, Fla., June 22, 2022 (GLOBE NEWSWIRE) -- Recovery First Treatment Center, a leading provider of substance use treatment services...
Rhythm Pharmaceuticals Announces that European Commission Authorized Variation for IMCIVREE® (setmelanotide) to Allow for Dosing in Patients with POMC or LEPR deficiency with Renal Impairment
BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the...
Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting
BELTSVILLE, Md., June 22, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing...
OpGen Announces Publication of Results of Unyvero Hospitalized Pneumonia (HPN) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized COVID-19 Patients
Results were published in the European Journal of Clinical Microbiology & Infectious Diseases Serial specimen analysis confirms correct detection of...
BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference
BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Rubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meeting
Prevention of Type 1 Diabetes in a Stringent Preclinical Model from Ongoing Experiment;Two Antigens Prevent Disease Driven by Many Autoantigens...
Recce Pharmaceuticals Announces Positive Safety Data from Sixth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
Highlights: 10 subjects in cohort six intravenously dosed with RECCE® 327 at 4,000mg demonstrated good safety and tolerabilityIndependent Safety Committee...